Current and emerging treatment options for hairy cell leukemia

OncoTargets and Therapy
Montserrat López-Rubio, Jose Antonio Garcia-Marco

Abstract

Hairy cell leukemia (HCL) is a lymphoproliferative B-cell disorder characterized by pancytopenia, splenomegaly, and characteristic cytoplasmic hairy projections. Precise diagnosis is essential in order to differentiate classic forms from HCL variants, such as the HCL-variant and VH4-34 molecular variant, which are more resistant to available treatments. The current standard of care is treatment with purine analogs (PAs), such as cladribine or pentostatin, which provide a high rate of long-lasting clinical remissions. Nevertheless, ~30%-40% of the patients relapse, and moreover, some of these are difficult-to-treat refractory cases. The use of the monoclonal antibody rituximab in combination with PA appears to produce even higher responses, and it is often employed to minimize or eliminate residual disease. Currently, research in the field of HCL is focused on identifying novel therapeutic targets and potential agents that are safe and can universally cure the disease. The discovery of the BRAF mutation and progress in understanding the biology of the disease has enabled the scientific community to explore new therapeutic targets. Ongoing clinical trials are assessing various treatment strategies such as the combination of PA an...Continue Reading

Citations

Mar 18, 2021·OncoTargets and Therapy·Qiuying LiuLeslie A Andritsos

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Clinical Trials Mentioned

NCT00412594
NCT00923013
NCT01059786
NCT01829711
NCT01841723

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

© 2021 Meta ULC. All rights reserved